Stockreport

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survi [Read more]